Showing results (41-50 of 4,234) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|May 14, 2021
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort studyNikolaus B Wagner, Max M Lenders, Kathrin Kühl, et al.Journal for Immunotherapy of Cancer|June 24, 2020
Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapyWilliam Murray-Brown, Tom D Wilsdon, Helen Weedon, et al.Journal for Immunotherapy of Cancer|June 24, 2020
Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodiesLambros Tselikas, Thierry de Baere, Thomas Isoardo, et al.Journal for Immunotherapy of Cancer|June 26, 2020
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cellsAnne W J Martens, Susanne R Janssen, Ingrid A M Derks, et al.Journal for Immunotherapy of Cancer|June 26, 2020
Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunityDawei Chen, Hampartsoum B Barsoumian, Grant Fischer, et al.Journal for Immunotherapy of Cancer|June 26, 2020
Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigensLaura Arribillaga, Iciar Echeverria, Viriginia Belsue, et al.Journal for Immunotherapy of Cancer|June 4, 2020
Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II studyKaichao Feng, Yang Liu, Yongtian Zhao, et al.Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.Journal for Immunotherapy of Cancer|April 19, 2020
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonistKarin M Knudson, Kristin C Hicks, Yohei Ozawa, et al.Journal for Immunotherapy of Cancer|April 19, 2020
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumorsCoya Tapia, Phyu P Aung, Sinchita Roy-Chowdhuri, et al.Pageof 424